KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.98

A phase III clinical trial evaluating efficacy and safety of minimal residual disease-based risk stratification for children with acute myeloid leukemia, incorporating a randomized study of gemtuzumab ozogamicin in combination with post-induction chemotherapy for non-low-risk patients (JPLSG-AML-20).

Daisuke Tomizawa, Shin-Ichi Tsujimoto, Shiro Tanaka, Jun Matsubayashi, Takahiro Aoki, Shotaro Iwamoto, Daisuke Hasegawa, Kozo Nagai, Kentaro Nakashima, Koji Kawaguchi, Takao Deguchi, Nobutaka Kiyokawa, Kentaro Ohki, Hidefumi Hiramatsu, Norio Shiba, Kiminori Terui, Akiko Moriya Saito, Motohiro Kato, Takashi Taga, Tsugumichi Koshinaga, Souichi Adachi

Jpn J Clin Oncol 52(10) 1225-1231

PMID35809896
PMCID-
DOI10.1093/jjco/hyac105
发表日期2022-07-09
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
摘要

摘要

The purpose of this study is to establish a treatment with appropriate intensity for children (<16 years old at diagnosis) with de novo acute myeloid leukemia (excluding acute promyelocytic leukemia and myeloid leukemia associated with Down syndrome) according to a risk stratification based on recurrent leukemic cytogenetic abnormalities and flow-cytometric minimal residual disease at end of initial induction chemotherapy and to validate the safety and efficacy of gemtuzumab ozogamicin (GO)-combined post-induction chemotherapy for the non-low-risk (non-LR) patients. The primary endpoint of this phase III study is three-year disease-free survival rate, which will be compared between the GO and non-GO arms of the non-LR (intermediate-risk and high-risk [HR]) patients. All HR patients will be allocated to allogeneic hematopoietic stem cell transplantation in first remission. This trial has been registered at the Japan Registry of Clinical Trials (jRCTs041210015).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。